Cardiovascular disease (CVD) accounts for the majority of deaths and most of the morbidity among persons with diabetes. 1 Given the large numbers of hypertensive persons, the agerelated character of rising blood pressure, and the coincidence of obesity with hypertension, it is not surprising that diabetesboth at onset and during its treatment-is so common among treated hypertensive persons. With the waist circumferences among populations tending to increase worldwide, the agerelated incidence of diabetes has increased to 2-3% annually in persons older than 65 years. 2 Indeed, the increasing incidence of adult-onset diabetes is now threatening to disrupt the long-standing pattern of declining cardiovascular mortality. 2, 3 New onset diabetes (NOD) has become an outcome of major interest in clinical trials of antihypertension therapy, as well as a matter of practical concern for both patients and their physicians. At the same time, despite the considerable clinical and epidemiological information now available, uncertainty continues to prevail regarding the causes, consequences, prevention, and treatment of NOD. 
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The epidemiology of Nod
The natural incidence of diabetes in untreated hypertensive persons has been demonstrated in the placebo-controlled SHEP (Systolic Hypertension in Elderly Program) Trial, reported in 1988. 4 SHEP participants were older and tended to have more evidence of CVD than the general hypertensive population, and 43% of control subjects eventually received active treatment, thus tending to mute the true magnitude of differences between treated and "untreated" subjects. Chlorthalidone was the active drug, but almost 50% of the actively treated participants were also exposed to β-blockers during the trial. The annual incidence of NOD was 2.7% in the placebo group, and nearly 50% higher (3.9%) in the treated group. The precision and generalizability of these findings are limited by participant selection, study characteristics, and the secular trends that have been in place since the study was completed. Nevertheless, the data do provide strong evidence that diuretics and β-blockers increase the risk of hyperglycemia and diabetes, while also establishing a benchmark for the natural incidence of NOD in hypertensive subjects.
Subsequent trials confirmed the adverse impact of diuretics and β-blockers. 5 It was hoped that newer antihypertensive agents, with more favorable metabolic mechanisms, would not increase the natural hyperglycemia associated with aging and hypertension. For the most part, but not invariably, newer agents have indeed realized that hope. For example, in the New onset diabetes (NOD) is common among hypertensive patients, whether they are being treated for hypertension or not, and is associated with subsequently increased cardiovascular disease (CVD). Thiazide-like diuretics and β-blockers are more likely to provoke hyperglycemia when compared with drugs that block the renin-angiotensin system, and calcium channel blockers. However, in contrast to the NOD arising during treatment with other antihypertensive drugs, the NOD that occurs during diuretic treatment, has not been shown to increase CVD, either in clinical trials, or during longer observational studies. In fact, blood pressure reduction achieved by diuretic treatment may avert the expected increase of CVD in NOD. Conventional blood pressure reduction (along with lipid lowering) is the proven approach to preventing CVD in diabetes, in whatever circumstances the diabetes occurs. apprehensions relating to the potential onset of NOD should not influence the choice of the initial antihypertensive treatment choice, nor should it invariably lead to discontinuation of diuretics (although such a step may reverse hyperglycemia). NOD can also sometimes be eliminated by correcting hypokalemia with a potassiumsparing diuretic, and/or potassium supplementation, or by adding a potassium-conserving antihypertensive drug such as an aCEI, aRB, or an anti-aldosterone agent. If all these stratagems fail (or are unsuitable), and the diuretic is essential to blood pressure control, then hypoglycemic therapy is indicated. NOD does adversely affect quality of life, and is not to be accepted lightly. However, diureticinduced hypergycemia can be managed, and should be tolerated if a diuretic is essential for blood pressure control. In summary, the potential for occurrence of NOD certainly needs consideration, but it is not an insurmountable challenge, and must not compromise aggressive blood pressure control, which remains the primary tool for antihypertensive care. 
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Losartan Intervention for Endpoint reduction (LIFE) trial, patients randomized to losartan had a 25% lower rate of NOD than those randomized to atenolol. 6 The actual percentages of NOD were 6 and 8%, respectively, and this was statistically significant. However, the absolute increment of NOD (241/4,605 vs. 319/4,588) was 1.7%. That is, only 78 out of almost 4,600 treated subjects were affected. This occurred in a setting wherein most participants in both groups also received diuretics at some point in the study.
The incidence of NOD with ACEI/ARB treatment as compared to the incidence with other treatments has been further assessed in a meta-analysis of 11 studies in cohorts with hypertension, heart failure, or CVD. These 11 studies employed a variety of agents as control intervention, although diuretics represented the control agent in the two largest studies. It should also be noted that exposure to diuretics was substantial in both arms of most of the studies. Nevertheless, despite these limitations, the meta-analysis revealed that the ACEI/ ARB groups had a 1.7% lower incidence of NOD than the control groups did. This excess, albeit significant, was modest, and meant that 58 subjects had to be treated with an ACEI and/or an ARB to prevent one occurrence of NOD. 7 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 8 the largest antihypertensive trial to date, compared the experiences of patients randomized to chlorthalidone, amlodipine, or lisinopril. The subjects in each randomized group received multiple additional drugs. In ALLHAT, by design, the second agent was atenolol, which was prescribed for ~25% of all the subjects, and equally across groups. The annual incidence of NOD was 2.45%-within the range in SHEP. But there were substantial differences between groups. As shown in Figure 1 , lisinopril-treated subjects fared best, with an annual incidence of 2.03%; for the amlodipine group it was 2.45% and the chlorthalidone group 2.9%. At 4 years, the cumulative incidence of NOD was 11.6% for the chlorthalidone group as compared with 8.1% for lisinopril subjects. Although this difference was measurable and significant, it is important to note that the net absolute incidence of NOD attributable to chlorthalidone was <1 case per 100 treated subjects per year. 9 From these multiple sets of comparative data it is not possible to determine whether it was the effect of a particular study drug, or any combination of the opposing effects of multiple drugs on glucose homeostasis that accounted for the observed differences in the incidence of hyperglycemia.
In an attempt to unravel that dilemma, the DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial was undertaken to find out whether a renin system blocking agent, ramipril, could prevent NOD. 10 Its 5,000 participants each had impired fasting blood glucose, were free of CVD, and included 43% with treated hypertension. Neither the incidence of NOD (18.1% vs. 19.5%), nor the final fasting blood glucose differed between the groups, but fasting blood glucose was more likely to regress in those randomized to ramipril than in the placebo group ( Table 1) . The hypertensive subgroup had the same experience as did the group as a whole. The fact that these trials involved a large number of subjects provides assurance that the estimate is robust, and permits one to draw the conclusion that a meaningful, albeit small advantage in glycemic control could be expected if new antihypertensive agents were to replace older ones.
It would therefore appear that agents that block the renin system (and probably calcium channel blockers as well) neither impair nor significantly improve glycemic control. The modestly higher incidence of NOD during antihypertensive drug treatment is most likely caused by the use of diuretics. The larger question is, however, whether the chlorthalidoneinduced rise in NOD also increases CVD incidence.
CVd aNd oTher CoNsequeNCes of Nod
A major concern is that drug-induced NOD amplifies the CVD risk in the hypertensive population that is already at 
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increased risk. This possibility was first raised in epidemiological studies. A systematic follow-up of 6,886 treated hypertensive subjects showed a link between NOD and subsequent CVD events. 11 The mean duration of follow-up was 6.3 years, with some subjects being studied for almost 20 years. Blood pressure during treatment averaged 138/83 mm Hg, and 70% of the patients maintained pressures <140/90 mm Hg. The risk of major CVD morbidity or mortality in patients with a history of diabetes was twofold greater than in those without (hazard ratio (HR) = 2.37, 95% confidence interval (CI): 1.80-3.11). Stratification by hyperglycemic status as (i) never; (ii) baseline only; (iii) follow-up only; and (iv) baseline and follow-up revealed a step-wise increase in the incidence of NOD (Figure 2) . The greater incidence of CVD in the presence of NOD was significant only in a subgroup that received diuretics >90% of the time. 11 Subsequently, analysis of a 6-year follow-up study of nearly 800 treated hypertensive Italian subjects revealed that the relative risk of CVD for those with prevalent diabetes was 3.57 (95% CI: 1.65-7.73) and for those with NOD it was 2.92 (95% CI: 1.33-6.41), relative to those who had never had diabetes. 12 The use of diuretics was associated with NOD, but only 12% of the subjects received diuretics alone.
Several more recent long-term studies have yielded results consistent with the hypothesis that NOD increases the risk of CVD. 13, 14 In an 18-year follow-up, among the >11,000 participants in The Multiple Risk Factor Intervention Trial, who had initially been free of diabetes and CVD, there were 1,846 deaths due to CVD (1,277 of which were due to coronary heart disease (CHD)). 13 HRs for CVD and CHD were 50% higher for those with NOD than for those without. Almgren et al. later identified 143 cases of NOD in a 25-28-year follow-up of 754 hypertensive men. 14 The incidence of stroke, heart attack, and total mortality were higher in those with NOD than in those without diabetes, but less than in those with prevalent diabetes (Figure 3) . Finally, in 15,000 high-CVD-risk participants in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, stratified according to diabetes status at entry, CHD morbidity was greatest for those with established diabetes (HR = 2.20, CI: 0.95-2.49, P = 0.0008), but NOD subjects also had a significantly higher risk of CHD (HR = 1.43, CI: 1.16-1.77, P < 0.0001) than drug-treated subjects who did not develop NOD. Heart failure was particularly common among those with NOD. 15 That NOD would increase CVD risk would be expected, given that diabetes is well known to increase CVD incidence in hypertension. Moreover, because CVD in diabetes is duration-dependent, and NOD duration falls somewhere between the duration for those who have never had diabetes and for those with prevalent diabetes, the increase in CVD incidence in NOD should be somewhere between the corresponding CVD increases in the other two categories. Aside from the modest increase in NOD provoked by diuretics, NOD during treatment probably reflects the natural influence of hypertension on the occurrence of hyperglycemia. However, it was only in the VALUE trial that increased CVD was seen during the 4 years of study. It is surprising that vascular complications of diabetes appeared in so short a time frame. This shows that it is possible that NOD in treated hypertensive patients may actually advance the occurrence of CVD. NOD did not, however, show association with increased CVD risk during the course of ALLHAT.
In part because of the concern about heightened CVD risk, testing for hyperglycemia is a routine feature of antihypertensive care. NOD is thereby readily identified, and compels 
the attention of both patients and physicians. Disease labeling can adversely affect patient mood and behavior. 16 Patients may be required to check their blood glucose with painful finger sticks. Physicians will invariably initiate further laboratory testing, both to confirm the diagnosis and to identify a potentially treatable cause-especially hypokalemia which is known to complicate diuretic use. 17 There is good evidence that glucose metabolism is impaired by hypokalemia. 18 Discontinuation of thiazide often returns the potassium balance to normal and corrects hyperglycemia. In this way NOD can stimulate a change in antihypertensive therapy and this intervention may have its own potential hazards. In addition, NOD might call for hypoglycemic therapy to avoid the microvascular consequences of diabetes. These personal, clinical, and economic burdens of NOD have not been quantified, but must be considered when assessing the importance of NOD.
does drug seleCTioN alTer CVd ouTComes?
Perhaps the critically important clinical question about NOD is whether its greater incidence in diuretic-treated subjects translates into increased CVD when compared with those who develop NOD during treatment with other antihypertensive agents. ALLHAT, the largest randomized clinical trial to compare antihypertensive agents, assessed both the incidence of NOD and its CVD consequences. 9 Because randomization to chlorthalidone was associated with increased NOD, one might have expected an adverse CVD effect. In the event, during 5 years of study, the primary endpoint and most of the secondary endpoints, as well as blood pressure, were actually either less frequent in the group randomized to the diuretic, or indistinguishable from the other groups. Of course, failure to detect any CVD difference in a rather short-term clinical trial does not rule out the possibility that harm would ultimately emerge. It is also possible that there were adverse effects, but in numbers insufficient to make a qualitative change in the outcome, and that it merely reduced the positive effect of the diuretic. Even the latter seems unlikely, because subjects randomized to chlorthalidone and who developed NOD actually had a lower incidence of CHD than did either the lisinopril or the amlodipine subjects who developed NOD. Most convincing was the finding that a 10% increase in fasting blood glucose at year 2 of the study was associated with an increase in CHD and total CVD exclusively in subjects randomized to lisinopril-and not in those randomized to chlorthalidone (Figure 4) .
It is also noteworthy that, in ALLHAT, randomization to doxazosin, an agent that has no adverse glycemic and other metabolic effects, was not associated with improved outcomes-quite the contrary. 19 The doxazosin arm was terminated prematurely, so it could be that a decrease in CVD and NOD risk were not detectable because of insufficient duration of treatment and follow-up. These data suggest that the higher incidence of NOD in patients on chlorthalidone treatment may reflect a different mechanism of hyperglycemia than conventional diabetes. 14 Barzilay et al. have suggested, but could not confirm, that the excess hyperglycemia associated with chorthalidone is most likely caused by hypokalemia. Hypokalemia-induced hyperglycemia is not associated with decreased insulin sensitivity and/or hyperinsulinemia, and thereby reflects a pathophysiology different from conventional type 2 diabetes. 14 Correction of hypokalemia can reverse hyperglycemia. 18 While this has not specifically been tested in thiazide-induced NOD, it is reasonable to assume that it would apply. Most compelling were the results of a meta-analysis of 11 trials, involving >100,000 subjects, the results of which showed that ACE/ARB-treated subjects had no greater protection against CVD mortality than did those treated with diuretics or with CCBs 20 ( Table 2) . 
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From these findings it is seen that clinical trials have failed to detect an adverse CVD consequence on account of NOD that is associated with diuretic use. While these short-term trials do not rule out the possibility of ultimate disadvantage, available evidence suggests that apprehension about the potential occurrence of NOD is not sufficient reason to tilt the balance in the matter of selecting the initial antihypertensive agent.
It is not likely that clinical trials will be mounted to address the issue of long-term consequences. The best available guidance for action may be found in the 18-year mortality follow-up of the participants in SHEP. 21 Although no information about the patients is available after the study terminated in 1988, there was complete and unbiased ascertainment of deaths through 2002 (14.3 years after the trial ended). Almost half of the "placebo" group had begun antihypertensive therapy before the end of the study, thus tending to minimize differences between the groups. CVD was more common in those with prevalent diabetes than in those with NOD. Nevertheless, among those who developed NOD, randomization to chlorthalidone led to better outcomes than those in the control subjects. Impressively, chlorthalidone-treated subjects who developed NOD had the same incidence of CVD events as did those without diabetes-control or treated ( Figure 5 )! This finding, although post hoc and the result of comparing groups not protected by randomization, suggests that NOD related to diuretic treatment may not increase CVD, at least when diuretic antihypertensive therapy has been used. Perhaps blood pressure control can trump lack of hyperglycemic control. Of course, because SHEP involved an elderly population, it is fair to say that its findings might not apply to younger patients.
CVd preVeNTioN iN persoNs wiTh diaBeTes
What do we know about CVD prevention in diabetes? The UKPDS study tested approaches to CVD prevention in type 2 diabetes. 22 Although it was completed more than a decade ago, with treatment goals less aggressive than those that are common today, its principle findings remain unchallenged. Disappointingly, superior glycemic control, to a HgA1c level of ~7, did not significantly reduce cardiovascular events, although microvascular outcomes were improved ( Table 3) . In contrast, better blood pressure reduction, albeit to levels above those sought today (systolic 154 mm Hg), did reduce CVD events. The Hypertension Optimal Treatment (HOT) study, which included 1,500 subjects with diabetes, was designed to determine whether the setting of lower target levels for blood pressure would improve CVD outcomes. 23 Overall, a lower BP did not improve CVD outcomes for the participants in the HOT study. However, the minority of the participants with diabetes did realize a dramatic stepwise reduction in CVD at target blood pressures ranging from 90 to 85 to 80 mm Hg (Figure 6 ). Lipid-lowering therapy is another approach proven to provide cardioprotection in patients with diabetes. The Heart Protection Study Collaborative Group carried out a 5-year randomized trial of statin therapy in 20,500 participants at high risk of CVD, with a wide range of LDL-C levels; 6,000 of the subjects were diabetic. 24 A statin-induced drop of 38 mg/dl (1.0 mmol/l) in LDL-C was associated with a 27% fall in CVD morbidity and mortality both in those with diabetes and those without. These studies indicate that, for patients with diabetes, as for all others, it is control of conventional risk factors rather than glycemic control, that best prevents CVD. 
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CoNClusioNs aNd CliNiCal impliCaTioNs
NOD is common among hypertensive patients, whether they are being treated for hypertension or not, and it is more likely to occur with the use of diuretics or β-blockers than with drugs that block the renin-angiotensin system and with calcium channel blockers. This probably reflects the fact that diureticinduced hypokalemia causes hyperglycemia, and the other drug classes do not have major effects on glucose homeostasis. NOD is associated with increased CVD risk in hypertensive persons, but there is no evidence, in short-term clinical trials, that excess NOD in diuretic-treated subjects has adverse CVD consequences. It has also been found, in a long-term observational study, that antihypertensive treatment with a diuretic actually eliminates the increase in CVD that would be expected in association with NOD. In fact, there is substantial evidence to indicate that blood pressure control (and lipid lowering) are the best means of preventing CVD in subjects with diabetes, whatever the circumstances in which the diabetes occurs. In summary, there is currently insufficient evidence to conclude that the potential occurrence of NOD should influence antihypertensive treatment choices. Clinical trials have consistently failed to show that newer agents provide cardioprotection superior to diuretics in patients with or without diabetes. That notwithstanding, it is also true that NOD is an unwelcome outcome of antihypertensive treatment. It frightens patients and probably generates microvascular complications. Although the magnitude of these consequences has not been quantified, they are likely to justify hypoglycemic therapy and thereby bring on the side effects (e.g., hypoglycemia) related to these agents. In short, NOD is a burden for patients as well as for the health care system. While apprehension about the potential occurrence of NOD should not determine initial antihypertensive therapy, its appearance will inevitably have therapeutic consequences. β-Blockers are frequently associated with NOD. When indicated for cardiac care, they must be maintained, and appropriate glycemic control efforts must be added. However, when not otherwise essential, blood pressure control can probably be achieved without a β-blocker. Thiazide-like diuretics are different. NOD is fairly common over the long course of diuretic use, and the discontinuation of diuretics may reverse the hyperglycemia. However, a diuretic is often an important component of optimal blood pressure treatment. If this is the case, either a lower dose, or a potassium sparing diuretic, and/or potassium supplementation, may correct the hyperglycemia. It is also sometimes possible to correct NOD by adding a potassium-conserving antihypertensive agent such as an ACEI, ARB, or an anti-aldosterone agent, along with the diuretic. This may mitigate hypokalemia, correct hyperglycemia, and permit reduction of the diuretic dose, without compromising blood pressure control. If all these stratagems fail (or are unsuitable), and a diuretic is essential for blood pressure control, then appropriate management of hyperglycemia may be initiated, keeping in mind that even the non-cardiovascular consequences of hyperglycemia are not to be accepted lightly.
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